Patricia M. Danzon

All Courses

• HCMG2040 - Comparative Hc Systems

  This course examines the structure of health care systems in different countries, focusing on financing, reimbursement, delivery systems and adoption of new technologies. We study the relative roles of private sector and public sector insurance and providers, and the effect of system design on cost, quality, efficiency and equity of medical services. Some issues we address are normative: Which systems and which public/private sector mixes are better at achieving efficiency and equity? Other issues are positive: How do these different systems deal with tough choices, such as decisions about new technologies? Our main focus is on the systems in four large, prototypical OECD countries--Germany, Canada, Japan, and the United Kingdom--and then look at other countries with interesting systems- including Italy, Chile, Singapore, Brazil, China and India. We draw lessons for the U.S. from foreign experience and vice versa.

• HCMG2150 - Mgmt&Econofpharma,Biotec

  This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

• HCMG8590 - Comparative Hc Systems

  This course examines the structure of health care systems in different countries, focusing on financing, reimbursement, delivery systems and adoption of new technologies. We study the relative roles of private sector and public sector insurance and providers, and the effect of system design on cost, quality, efficiency and equity of medical services. Some issues we address are normative: Which systems and which public/private sector mixes are better at achieving efficiency and equity? Other issues are positive: How do these different systems deal with the tough choices, such as decisions about new technologies? Our focus first on the systems in four large, prototypical OECD countries- Germany, Canada, Japan, and the United Kingdom -and then look at other developed and emerging countries with interesting systems - including Italy, Chile, Singapore, Brazil, China and India. We will draw lessons for the U.S. from foreign experience and vice versa.

• HCMG8630 - Mgmt&Econofpharm&Biotech

  This course explores the key phases of the pharmaceutical and biotechnology product lifecycle. The product journey begins in the lab where scientists explore a vast array of compounds against diseases (therapeutic targets). Compounds that perform best enter the capital-intensive clinical trial phase aimed at assessing the product’s safety and efficacy. In parallel, regulatory agencies guide and govern these trials and ultimately decide which products are approved for use in patients. Once approved, launched, and priced, products face many dynamic market forces including competitors trying to steal share, government and private payers placing downward pressure on price, regulatory agencies controlling what manufacturers can and cannot say about their products, generic manufacturers challenging existing patents, and finally patients and physicians who behave both rationally and irrationally when deciding which product to use. While the course perspective is global in nature, the emphasis is on the U.S., the largest and most profitable market. In addition, we will delve into the world of biotech start-ups from company creation and financing, to how they make decisions which compounds to advance. We will also explore how large pharma views the biotech industry to bolster their existing pipelines and drive shareholder value. Through case studies, readings, guest speakers, and in-class exercises, students will learn concepts and analytical frameworks and acquire the tools and skills necessary to become the future leaders of the pharmaceutical and biotech industry.

• HCMG8900 - Advanced Study Project

  HCMG 8900-001: This course examines issues related to the Services Sector of the health care industry. For those interested in management, investing, or banking in the health care industry, the services sector will likely be the largest and most dynamic sector within all of health care. We will study key management issues related to a number of different health care services businesses with a focus on common challenges related to reimbursement, regulatory, margin, growth, and competitive issues. We will look at a number of different businesses and subsectors that may have been unfamiliar to students prior to taking the course. We will make extensive use of outside speakers, many of whom are true industry leaders within different sectors of the health care services industry. Speakers will address the current management issues they face in running their businesses as well as discuss the career decisions and leadership styles that enables them to reach the top of their profession. Students will be asked to develop a plan to both buy out and manage a specific health care services business of their choosing and will present their final plans to a panel of leading Health Care Private Equity investors who will evaluate their analysis. Prerequisites: HCMG 8410. Health Care Management MBA majors only

• HCMG8990 - Independent Study

  Arranged with members of the Faculty of the Health Care Systems Department. For further information contact the Department office, Room 204, Colonial Penn Center, 3641 Locust Walk, 898-6861.

• Agency for Health Care Research and Quality, John M. Eisenberg Excellence in Mentorship Award, 2012
• American Risk and Insurance Association, Award for Outstanding Article, for “Alternative Liability Regimes for Medical Injuries: Evidence from Simulation Analysis,” August, 1995
• American Association of Risk and Insurance, Award for Outstanding Article, for “Compensation for Occupational Disease: Evaluating the Options,” Journal of Risk and Insurance, June, 1987
• American Risk and Insurance Association, Elizur Wright Award, for Medical Malpractice: Theory, Evidence and Public Policy, June, 1987

Knowledge at Wharton

• Is the U.S. Ready for Value-based Pricing of Drugs?, Knowledge at Wharton - 5/18/2016
• Technology Increasingly Key to Better Patient Outcomes, Knowledge at Wharton - 12/16/2014
• ‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush, Knowledge at Wharton - 5/28/2014
• Sovaldi: Who’s to Blame for the $1,000 a Day Cure?, Knowledge at Wharton - 4/16/2014
• Biotech IPOs: What Entrepreneurs Can Learn from a Banner Year, Knowledge at Wharton - 1/22/2014
• Access or Profits? Drug Patent Rulings in India Fuel the Debate, Knowledge at Wharton - 4/10/2013
• Patent Controversy Resumes as Indian Supreme Court Rejects Novartis’ Glivec Claim, Knowledge at Wharton - 4/2/2013
• Accountability in Health Care — Collaboration and Analytics Are Key, Knowledge at Wharton - 1/16/2013
• Health Rates to Rise, but the Expected Impact Is Unclear, Knowledge at Wharton - 1/11/2013
• Fixing Health Care: The Next Big Challenge, Knowledge at Wharton - 6/29/2012